Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

Summary

Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug.

Timeline

Start

2026-11

Primary completion

2028-06

Completion

2028-11

Drugs

Indications